Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A multiomics profiling study to classify the origin of Cancers of Unknown Primary (CUP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
A Phase 3, Open-Label, Randomized, 2 Part Study Comparing Gedatolisib in Combination with Palbociclib & Fulvestrant to SoC Therapies in Patients with HR+ HER2- Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor with Non-Steroidal AI Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
An Investigation of a Working Memory Training Program for Neurological Surgery Patients with Various Diagnoses
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 11, 2023
A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 12, 2023
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 12, 2023
Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 Administered in Patients With Relapsed/Refractory AML or Newly Diagnosed High-Risk AML
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 12, 2023
Prognostic Significance of Circulating Tumor Cells in Prostate Cancer: A Pilot Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 26, 2023
Prospective longitudinal bio-specimen collection in patients with early breast cancer patients who receive pre-operative systemic therapy, post-operative adjuvant systemic therapy, and metastatic breast cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 26, 2023
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 4, 2023
Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab consolidation in patients with minimal residual disease positivity
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 4, 2023